BRL Medicine is a platform-based biotechnology company focused on the research, development, and clinical application of gene and cell therapies. Leveraging our capabilities in gene editing technologies and a combination of six modularized platforms, we have independently developed a comprehensive product pipeline of innovative therapeutic solutions for conditions in the areas of genetic diseases, autoimmune diseases, hematologic malignancies and solid tumors, each with significant medical needs but yet effective solutions, thereby leading to vast market potential. Since our inception, BRL Medicine has evolved from building our core technology platforms and research capabilities to advancing our product candidates toward the commercialization stage.
Dedicated to the development and translation of gene editing and cell therapy and gene therapy for genetic diseases caused by gene mutations
Nearly 100 people
100+
Has six modular technology platforms
BRL Medicine, leveraging its core gene-editing technology and six modular technology platforms, has built a product pipeline covering genetic diseases, autoimmune diseases, hematological malignancies, and solid tumors. Among them, gene editing projects for β-thalassemia, non-viral site‑specific integration PD1‑CAR‑T and UCAR‑T have achieved excellent clinical results.
Won BIOCHINA Awards
BRL-303, an allogeneic universal CAR-T product, has received IND clearance in China for the treatment of SLE.
BRL-201, a non-viral PD1-CAR-T therapy utilizing site-specific integration, debuted its latest long-term follow-up data at the 2025 ASH Annual Meeting.
BRL-101 successfully freed a 5-year-old thalassemia patient from transfusion dependence in a Phase II registrational clinical trial.
Professor Mingyao Liu, Founder & Chairman , has been honored with the 8th Outstanding Contribution to Translational Medicine Award.
Selected for the 2025 China Biopharma Front-Runners Top 100
BRL-303 UCAR-T Cell Therapy for SLE Selected for Poster Presentation at ACR Annual Meeting
BRL-101 Gene Therapy Unveiled at China-ASEAN Expo, Offering a Chinese Solution for Thalassemia.
First BRL-201 (PD1-CAR-T) patient cancer-free >5 years.
Designated as a "Shanghai Municipal Enterprise Technology Center".
Awarded "BioCon Awards 2025-Annual Investable Innovation Enterprise".
Published 2 papers in Nat Biotechnol: Achieved first global "precise repair" of in vivo mitochondrial DNA.
Won CGCS Awards "CGT R&D Excellence Rising Star Award".
Listed on "2025 BEYOND Awards MedTech List".
Published in Cell Res: Confirmed success of world's first allogeneic UCAR-T (BRL-301) treating r/r SLE.
Ranked Top 100 on VB100 "China Innovative Pharma & Biologics List".
Awarded the 2024 Shanghai Science and Technology Progress Prize (First Prize)
BRL-101 & BRL-303 progress selected for ASGCT & EHA 2025.
Published major review in Cancer Cell guiding solid tumor immunotherapy.
IND approval for BRL-301 UCAR-T in new indication (r/r B-cell NHL).
Won APAC CGT Star "Annual Most Influential Innovative Therapy Company".
Published in Nat Biotechnol: Developed novel RNA editor "PA-rABE" for genetic disease therapy.
BRL-303 research named among "2024 China Top 10 Scientific Advances".
BRL-303 research named among "2024 China Top 10 Biotech Advances".
Published in Mol Ther: Developed innovative CAR-T enhancing solid tumor efficacy.
BRL-303 research named "Cell Line: 2014-2024" by Cell.
BRL-303 research named among "2024 China Top 10 Life Sciences Advances".
BRL-303 research named among "2024 China Top 10 S&T Advances" (CAS/CAE selected).
Recognized as Shanghai Excellent Patent Model Unit.
BRL-303 research named "Best of Cell 2024".
BRL-303 research named among "2024 Top 10 Clinical Breakthroughs".
BRL-303 research named among "2024 Top 10 Int'l & Domestic S&T News" (Science and Technology Daily) .
Won "Annual Investment Value Award" (5th China Biopharma Innovation List).
Announced success of BRL-102 gene therapy for China's first foreign SCD patient.
Completed ~200M RMB B+ financing.
Won "Outstanding Award" at 4th Biotech Rising Star Competition.
World's first IND approval in China for "BRL-203" (non-viral PD1-targeted CAR-T for lupus).
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2024".
Ranked Top 20 "2024 BioManufacturing Rising Star".
BRL-303 research featured in Nature headline.
First BRL-201 (PD1-CAR-T) patient cancer-free >4 years.
BRL-303 research highly praised by Prof. Carl June in Cell.
Ranked Top 10 Most Influential CGT Company (Huayi Chart).
Won "Outstanding Project" at Precision Medicine Innovation Competition.
Won "Rare Disease Industry Promotion Award" (4th Golden Snail Award).
BRL-303 UCAR-T lupus research highlighted in Nat Rev Rheumatol.
Published in Mol Cell: Developed novel compact, hyperactive IscB-based gene editor.
Published in Cell: World's first success with allogeneic UCAR-T (BRL-303) treating autoimmune disease.
Ranked Top 30 Innovative Novel Therapeutics Biopharma (China Biopharma Innovation List).
Awarded "2024 CGT Rising Star Enterprise of the Year".
BRL-201 progress presented at ASCO.
BRL-101 & BRL-201 progress presented at EHA.
BRL-101 progress presented at ASGCT (2nd consecutive year), and the latest clinical progress was orally reported.
Awarded "2024 top 100 list of innovative pharmaceutical and biological products in China" by VB100, and "2024 VBEF list of innovative products in the medical and health industry".
Reported promising efficacy of UCAR-T (with Zhejiang FAH) in refractory lupus, enabling patient cessation of traditional drugs.
Won "CGT Star: Outstanding Innovative Pipeline Award".
Published in Nat Chem Biol: Developed haA3A-CBE high-precision editor.
Won Future Industry Rising Star Award (Project Group).
Won "Zhuoyao Rising Star Enterprise".
BRL-101 research featured on CCTV Dialogue.
Won "2023 Most Investable Rising Star" (China Biopharma Innovation List).
Ranked Top 10 Most Promising Novel Cell Therapy Company (Huayi Chart).
BRL-101 & BRL-201 progress presented at ASH.
Orally Presented BRL-201 (next-gen non-viral PD1-CAR-T) data at SITC.
Ranked Top 10 on "2023 Dalinghao Bay Innovation & Entrepreneurship Influence List".
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2023".
World's first BRL-201 (non-viral PD1-CAR-T) patient cancer-free >3 years.
Strategic partnership with Porton Biologics to accelerate CGT industrialization.
Advanced to China Innovation & Entrepreneurship National Finals.
BRL-201 progress presented at ASGCT & SITC, and the latest clinical progress was orally reported.
IND approval for next-gen UCAR-T "BRL-301" in China.
Published in Mol Ther: Developed innovative CAR-T enhancing solid tumor efficacy.
Awarded "2023 China Biopharma Value: Top 10 Most Influential Innovative Therapy Companies".
Awarded "Top 30 Innovative Novel Therapeutics Biopharma".
Awarded "BioCon Awards 2023-Most Investable Rising Biotech Star".
Published in Nat Biotechnol: Developed ACBEs transversion editor.
Awarded "2023 Top 10 Most Influential CGT Companies".
BRL-201 published in Lancet sub-journal.
Awarded "Thalassemia Caring Tech Enterprise".
First public presentation of BRL-101 data at ASGCT.
IND applications for CD19 UCAR-T products BRL-301 & BRL-301A accepted in China.
BRL-101 cured 2 adult severe thalassemia patients in Phase 1 trial.
BRL-201 named among "2022 China Important Medical Advances".
Awarded "CGT Star 2023: Best Technology Breakthrough Award".
Awarded "2022 Top 100 Breakthrough Innovation Companies".
BRL-201 entered registrational clinical study.
Recognized as Shanghai "Specialized, Sophisticated, Distinctive, Innovative" SME.
First thalassemia patient cured in BRL-101 Phase 1 trial.
BRL-201 (non-viral CAR-T) named among "2022 Top 10 Hematology Research Advances in China".
Completed >200M RMB Series B financing.
Awarded "2022 Most Promising Newcomer", "2022 Most Applicable Key Tech Platform" (hematopoietic stem cell platform, non viral fixed-point integration car-t platform).
IND approval for "Targeting CD19 Non viral PD1 Targeted Integration CAR-T Cell Injection" (pipeline code: BRL-201) in China.
First patient dosed in BRL-101 Phase 1 trial.
Non-viral CAR-T tech won "2022 S&T Achievement Transformation Award" (Southern Weekly).
Recognized as Shanghai Patent Model Unit.
Founder Prof. Mingyao Liu named "Annual Influential Leader in China CGT".
Ranked Top 10 Most Promising Innovative Therapy Company.
Published in Nat Biotechnol: Developed high-precision Td-CGBE/Td-CBEs editors.
Thalassemia research were selected into the report of "The Payment for Rare Disease Drugs to Promote Common Prosperity in China (2022) ".
Published in Nat Chem Biol: Developed precise ABE9 base editor.
Recognized as National IP Advantageous Enterprise.
For two consecutive years: "Top 30 Most Innovative New Technology Pharmaceutical Enterprises in China" and "Top 100 Innovative Seed Pharmaceutical Enterprises in China."
Published in Nature: BRL-201 (non-viral PD1-targeted CAR-T) achieved >2-year cancer-free survival in NHL patient.
IND approval for "BRL-101 autologous hematopoietic stem and progenitor cells injection" (Pipeline code: BRL-101) in China.
Awarded "2022 China biomedical industry value list - top20 most influential innovative therapy enterprises".
Published in Nat Med: BRL-101 gene therapy enabled thalassemia child transfusion independence >2 years.
Awarded "2022 top 100 future medical treatment - China's top 100 innovative medicine list" and "2022 top ten value fields list - TOP10 in gene therapy".
Awarded "top 100 pharmaceutical innovative seed enterprises in China in 2021".
Gene therapy achieved transfusion independence for 6 thalassemia children nationwide.
Recognized as Shanghai Excellent Patent Pilot Unit.
Awarded "2021 biological innovative drug most growth annual award".
Appointed research partner by Hunan Genetics Society Rare Disease Committee.
Awarded "2021 top 100 future medical treatment - China's top 100 innovative medicine list" and "2021 biomedical value field list - TOP10 in the field of cell and gene therapy".
Ranked Top 30 Innovative Novel Therapeutics Biopharma Company (China).
Established internship base with ECNU.
Cured 3 thalassemia children in Guangxi (with 923 Hospital).
Thalassemia breakthrough featured in ZHONGGUO DIZHONGHAI PINXUE LANPISHU (2020).
Awarded "2020 China Health New Force Enterprise".
6000 sqm GMP pilot base operational.
Obtained IP Management System Certification.
Released world's first clinical data: CD19-PD1-Quickin-CART successfully treated lymphoma (with Zhejiang University FAH).
Published in Nat Biotechnol: Developed novel dual base editing system.
Published in Nat Med: Demonstrated next-gen base editing potential for hereditary blood diseases.
Ranked Top 5 in Universal CAR-T (Future Healthcare 100 China).
Awarded multi-million RMB funding from Shanghai Zhangjiang National Key Project (H25).
Ranked among China's Top 50 Most Innovative Biopharma Companies.
Published in Nat Med: Gene therapy potential for curing hereditary blood diseases.
1000 sqm GMP-like pilot base operational.
Awarded National High-Tech Enterprise status.
Recombination of BRL Medicine and establishment of "Shanghai Research Center for Gene Editing and Cell Therapy".
BRL Medicine Inc. was incorporated in Shanghai.